The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-10-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerchemotherapyconcurrentventriculartreated
  Phrases that lowered it: administration ofeffectevaluate therangeto evaluate
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 8.3% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 32084 (raises risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 405898 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 26 (lowers risk) · Sponsor's track record
• Maximum age: 65 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 72.4% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 11 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients NCT05338723 · started 2020 · scored riskier than 13% of active trials completed
• Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer NCT00955890 · started 2009 · scored riskier than 96% of active trials terminated
• Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) NCT01988571 · started 2014 · scored riskier than 73% of active trials completed
• Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane NCT03930680 · started 2021 · scored riskier than 21% of active trials completed
• STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines) NCT02943590 · started 2017 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.